NDAORALTABLET
Approved
Dec 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ALDORIL D50 (hydrochlorothiazide; methyldopa) by Merck & Co. is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 1962.
Drug data last refreshed 23h ago
Mechanism of Action
Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…
Indications (1)
Worked on ALDORIL D50 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.